Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Testing the Feasibility of Using an Epigenetic Marker, p16, to Promote Smoking Cessation

NCT01038492 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT01038492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01038492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Testing the Feasibility of Using an Epigenetic Marker, p16, to Promote Smoking Cessation
Lead sponsor
Duke University
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2009
Completion date
June 30, 2010
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, smoking cessation, tobacco use disorder